what are the benefits of tirzepatide for type 2 diabetes patients?

 Tirzepatide is a medication that is FDA approved for the treatment of type 2 diabetes mellitus

11

. It is a dual GIP and GLP-1 receptor agonist, which means that it works by stimulating both the GIP and GLP-1 receptors in the body

3

.Tirzepatide has been shown to be effective in reducing body weight in overweight and obese patients with type 2 diabetes. In a global phase 3 trial, patients with obesity and type 2 diabetes or with overweight and type 2 diabetes lost an estimated 34.4 pounds (15.7%) of body weight with 10 mg and 15 mg of tirzepatide

9

. The SURMOUNT-2 study found that individuals with type 2 diabetes and obesity lost an average of 15% of their body weight after 72 weeks of treatment with tirzepatide

14

.In addition to weight loss, tirzepatide has been shown to be effective in improving blood sugar control in adults with type 2 diabetes. In clinical trials, all doses of tirzepatide demonstrated superiority in reducing A1C and body weight from baseline versus placebo or active comparators

5

. Tirzepatide works to stimulate first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner

2

. It also delays gastric emptying, lowers fasting and postprandial glucose levels, and reduces food intake

2

11

.Tirzepatide is administered as a once-a-week subcutaneous injectable

2

. It is currently implemented as a second-line diabetes medication, similar to GLP-1 medications

3

. Tirzepatide is also being studied for its potential use in treating obesity

12

.In summary, tirzepatide has been shown to be effective in reducing body weight and improving blood sugar control in adults with type 2 diabetes. It works by stimulating both the GIP and GLP-1 receptors in the body, which results in reduced glucagon levels, delayed gastric emptying, lower glucose levels, and reduced food intake. Tirzepatide is administered as a once-a-week subcutaneous injectable.

Citations:

[1] https://jamanetwork.com/journals/jama/fullarticle/2788799

[2] https://pubmed.ncbi.nlm.nih.gov/35929488/

[3] https://www.fiercepharma.com/pharma/lilly-s-tirzepatide-doesn-t-necessarily-top-diabetes-rivals-jardiance-and-ozempic-icer-says

[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10231274/

[5] https://diabetesjournals.org/clinical/article/41/2/258/148021/Efficacy-and-Safety-of-Tirzepatide-in-Adults-With

[6] https://www.healthline.com/health/tirzepatide-vs-semaglutide

[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268041/

[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987449/

[9] https://www.frontiersin.org/articles/10.3389/fphar.2022.1016639/full

[10] https://www.nature.com/articles/s41591-023-02344-1

[11] https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes

[12] https://www.joincalibrate.com/resources/tirzepatide-vs-semaglutide

[13] https://investor.lilly.com/news-releases/news-release-details/lillys-tirzepatide-achieved-157-weight-loss-adults-obesity-or

[14] https://diabetes.org/newsroom/press-releases/2023/surmount-2-study-finds-individuals-type%202-diabetes-obesity-lost-average-15-percent-body-weight-taking-tirzepatide

[15] https://www.nejm.org/doi/full/10.1056/NEJMoa2107519